DalCor Pharmaceuticals
Phase 3DalCor is developing dalcetrapib, a precision pharmacogenetic medicine for patients with a heart attack to reduce the risk of recurrent myocardial infarction.
Founded
2015
Focus
Small Molecules
About
DalCor is developing dalcetrapib, a precision pharmacogenetic medicine for patients with a heart attack to reduce the risk of recurrent myocardial infarction.
Funding History
2Total raised: $150M
Series B$100MAndera PartnersJun 15, 2018
Series A$50MAndera PartnersJan 15, 2016
Company Info
TypePrivate
Founded2015
LocationMontreal, United States
StagePhase 3
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile